Particulars (Rupees in Crores.) | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 | Sept-2022 |
---|---|---|---|---|---|
Gross Sales | 276.06 | 338.58 | 262.87 | 272.54 | 282.97 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 276.06 | 338.58 | 262.87 | 272.54 | 282.97 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 12.17 | 6.27 | 5.31 | 7.09 | 3.23 |
Total Income | 288.23 | 344.85 | 268.18 | 279.63 | 286.2 |
Total Expenditure | 259.88 | 307.17 | 234.68 | 240 | 255.49 |
PBIDT | 28.35 | 37.68 | 33.5 | 39.63 | 30.71 |
Interest | 0.04 | -0.03 | 0.12 | -0.14 | 0.26 |
PBDT | 28.31 | 37.71 | 33.38 | 39.77 | 30.45 |
Depreciation | 12.39 | 12.45 | 13.99 | 15.51 | 16.79 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 6.26 | 5.15 | 7.07 | 0 | 0 |
Deferred Tax | 4.92 | 2.74 | 1.2 | 9.92 | 1.44 |
Reported Profit After Tax | 4.74 | 17.37 | 11.12 | 14.34 | 12.22 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 4.74 | 17.37 | 11.12 | 14.34 | 12.22 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 4.74 | 17.37 | 11.12 | 14.34 | 12.22 |
EPS (Unit Curr.) | 3.54 | 12.99 | 8.32 | 10.73 | 9.14 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 13.37 | 13.37 | 13.37 | 13.37 | 13.37 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 10.26 | 11.12 | 12.74 | 14.54 | 10.85 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 1.71 | 5.13 | 4.23 | 5.26 | 4.31 |
Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice